INSUBCONTINENT EXCLUSIVE:
NEW DELHI: Shares of Sun Pharma dipped over 4 per cent in early trade on Wednesday after the pharma major posted a consolidated loss of Rs
218.82 crore for the quarter ended September 30, on a one-time loss of Rs 1,214.38 crore with respect to Modafinil antitrust litigation.
The
scrip was trading 4.31 per cent down at Rs 537.50 at around 10.00 am (IST), while the benchmark BSE Sensex was down 0.19 per cent at
The consolidated total revenue for the company increased 4.32 per cent year-on-year to Rs 6,937.63 crore during the quarter under review
against Rs 6,650.34 crore in the same period last year
Ebitda rose to Rs 1,530.90 crore during the September quarter against Rs 376 crore last year
Meanwhile, the shares of Sun Pharma opened at Rs 558.50 on BSE against its previous close of Rs 561.70
